MET and central nervous system cancer: When we compared tissue sections from MET+ and MET- gliomas, we observed a strong expression of the glioma MES-like marker CD4456, and the abundance of hypoxic areas in MET+ tumors, confirming the mesenchymal character of these gliomas (Fig. 7H).